Document is current

Any future updates will be listed below

Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries

Crossref DOI link: https://doi.org/10.1007/s00277-025-06601-w

Published Online: 2025-09-20

Published Print: 2025-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark